Dendrimer-encapsulated camptothecins: increased solubility, cellular uptake, and cellular retention affords enhanced anticancer activity in vitro

Cancer Res. 2006 Dec 15;66(24):11913-21. doi: 10.1158/0008-5472.CAN-06-2066.

Abstract

A biocompatible polyester dendrimer composed of the natural metabolites, glycerol and succinic acid, is described for the encapsulation of the antitumor camptothecins, 10-hydroxycamptothecin and 7-butyl-10-aminocamptothecin. The cytotoxicity of the dendrimer-drug complex toward four different human cancer cell lines [human breast adenocarcinoma (MCF-7), colorectal adenocarcinoma (HT-29), non-small cell lung carcinoma (NCI-H460), and glioblastoma (SF-268)] is also reported, and low nmol/L IC(50) values are measured. Cellular uptake and efflux measurements in MCF-7 cells show an increase of 16-fold for cellular uptake and an increase in drug retention within the cell when using the dendrimer vehicle.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents, Phytogenic / pharmacokinetics
  • Antineoplastic Agents, Phytogenic / therapeutic use
  • Biocompatible Materials
  • Biological Transport
  • Brain Neoplasms
  • Breast Neoplasms
  • Camptothecin / pharmacokinetics*
  • Camptothecin / therapeutic use*
  • Capsules
  • Carcinoma, Non-Small-Cell Lung
  • Cell Line, Tumor
  • Colorectal Neoplasms
  • Dendrimers / pharmacokinetics*
  • Dendrimers / therapeutic use
  • Female
  • Glioblastoma
  • Humans
  • Lung Neoplasms
  • Magnetic Resonance Spectroscopy
  • Solubility

Substances

  • Antineoplastic Agents, Phytogenic
  • Biocompatible Materials
  • Capsules
  • Dendrimers
  • Camptothecin